The formulation containing HPMC K15MCR and Polyox WSR at the Sorry, there is no online preview for this file type. Ranitidine can be found in many pharmaceutical firms such as tablets, injectable solutions and oral Dissolution enhancement of aceclofenac tablet by solid dispersion technique. short biological half life demands continuous intravenous infusion or time spaced injection. We chose tristearin as solid lipid and formulated it in nanoparticulate form by an ultrasonic Sorry, there is no online preview for this file type. Enhanced skin delivery of aceclofenac via hydrogel-based solid lipid nanoparticles. Injectable. Moderate. REACTION TO SEPTRIN PROPHYLAXIS IN A NEWLY STARTED SWEATING WITH CHANGE IN HAEMODYNAMIC STABILITY. 1. 1 Injectable. Mild. 2. ORAL DICLOFENAC 50MG, HAEMOPTYSIS.
|Published (Last):||22 February 2014|
|PDF File Size:||11.80 Mb|
|ePub File Size:||10.8 Mb|
|Price:||Free* [*Free Regsitration Required]|
Preclinical studies demonstrated that aceclofenac not only has a superior therapeutic activity but also a more favourable ulcerogenic index than diclofenac, phenylbutazone or indomethacin. In addition, aceclofenac was found to be highly active against sodium urate-induced synovitis in dogs and adjuvant-induced polyarthritis in rats, both prophylactically and therapeutically. The sterilized aqueous solution of aceclofenac was flushed with the sterile nitrogen gas, aseptically, and 5 mL volumes were filled into vials and capped with slotted rubber plugs.
Table 1 Hydrotropic blends selected for aceclofenac. In case of dilution with the normal saline solution the precipitation was observed within 24 h of 1: US DMF type requires module 3 and admin information.
Table formularion Equilibrium solubility of aceclofenac in different media. Such compositions are useful in treatment of pain and inflammation caused by angiogenesis-related disorders in a subject, for example to inhibit tumor angiogenesis. Further, these tubes can be printed in multi-color elegantly. Still another object of the present invention is to provide Aceclofenac injection when giving oral dose to patient is not possible.
Rajkumar Gupta – Google+
Wait while more posts are being loaded. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention. A stable lyophilized preparation of rocuronium bromide and preparation method thereof. Many other variations are possible. Accordingly, the objects and advantages of the present invention are described as below:.
US20090156670A1 – Nonaqueous liquid parenteral aceclofenac formulation – Google Patents
fuletype As such no aqueous injectable preparation of aceclofenac is commercially available. Looks like you’ve reached the end.
Table 4 R f values of aceclofenac and solubilized product. Such compositions can be used to treat subjects having adenomatous polyps, including those with familial adenomatous polyposis FAP. Essel Propack Limited Nalagarh Unit 7. As specified in 21 CFR The solubility of aceclofenac increases slightly, with an increase in pH maximum 4 timeswhich may be due to the acidic nature of aceclofenac.
The polyethylene glycol has an average molecular weight ranging from about to about and preferably from about to about Where the stated range includes one or both of the limits, ranges excluding either both of those included limits are also included in the invention. It is evident from the literature survey that increasing the concentration of hydrotrope could increase the aqueous solubility of poorly water-soluble drugs. The salicylic acid derivative component of the present invention helps to stabilize the injection and improve efficiency.
If a liquid parenterally deliverable formulation of Aceclofenac or a pharmaceutically acceptable salt thereof, particularly such a formulation that is ready-to-use, that is storage stable at room temperature could be prepared, a significant advance in treatment of COX-2 mediated conditions and disorders would result.
Parenteral drug formulations have become a very important component in the arsenal of available drug delivery options, particularly for drugs having analgesic effect. Hydrotropic agents have been observed to enhance the aqueous solubility of poorly water-soluble drugs 2 – The Aceclofenac formulation of claim 1wherein said Aceclofenac salt comprises a phenyl acetic acid derivative with anti-inflammatory analgesic properties.
A process for preparing a nonaqueous liquid parenteral Aceclofenac formulation for pharmaceutical application, which process comprises the steps of: Essel Propack Ltd Murbad Unit Injectiln the present invention for pharmaceutical composition of aceclofenac and process for its preparation, the therapeutic effective amount of aceclofenac that may be used is in the range from inkection mg to about mg per day.
If a parenteral drug formulation is to be prepared, it is preferable from patient convenience and safety standpoints that such a formulation be a ready-to-use formulation, i.
Arginine is a conditionally nonessential amino acid, meaning most of the time it can be manufactured by the human body, and does not need to be obtained directly through the diet. In addition, when being orally administered in an amount much smaller than the conventional preparation, the oral preparation is therapeutically effective, thus minimizing gastrointestinal disorder.
US Patent application publication no. The vials were subjected to stability studies by keeping them at different temperature and humidity conditions. The Aceclofenac formulation of Item 11, wherein concentration of said Benzyl alcohol is in the range from about 0.
USA1 – Nonaqueous liquid parenteral aceclofenac formulation – Google Patents
The proposed hydrotropic agents are known to be safe. The said molar ratio of arginine to aceclofenac ensures the solubility of aceclofenac in the aqueous solution. In the present work, aceclofenac, a non-steroidal formulatio agent was selected as a model drug which is a BCS class II drug highly permeable and low ffiletype and attempts were made to formulate an aqueous injection of this drug, using various hydrotropic agents.
Aceclofenac 2-[ 2,6-dichlorophenyl amine]phenylacetoxyacetic acid; CAS is a new orally effective non-steroidal anti-inflammatory agent of the phenylacetic acid group which showed remarkable anti-inflammatory, analgesic, and antipyretic properties. Preferably, the Aceclofenac salt is administered in a daily dosage amount of about 1 mg to about mg. Please contact us for filing new DMF fotmulation amending the existing one.